Anthropic 以四億美元併購 AI 生技新創 Coefficient Bio

According to reporting by The Information and TechCrunch, Anthropic completed its acquisition of Coefficient Bio for $400 million. Coefficient is a New York–headquartered biotech startup. Its R&D focus is on using AI models and simulated biological sequence data to discover new drugs.

Coefficient Bio startup team background

Coefficient Bio is based in New York and is a lean team of only about 10 people, founded in 2025. The company is led by CEO Aris Theologis, who previously worked at Evozyne and Paragon Biosciences and brings extensive industry experience. The technical team is co-led by Nathan Frey, a scientist formerly at Biogen, and Joyce Hong from Roivant Sciences; some members also have computational drug discovery backgrounds from Prescient Design, a unit under Genentech.

What kind of company is Coefficient Bio?

Coefficient Bio uses AI models to optimize the drug discovery (Drug Discovery) process. Traditional drug development often faces challenges such as overly long development cycles, high costs, and low success rates. According to reports, the company’s technology can improve the efficiency of drug research. After this team—made up of senior drug discovery experts and scientists—joins Anthropic, it will directly be added to Anthropic’s healthcare and life sciences division. This kind of technology integration enables AI models to provide support with greater professional depth and scientific accuracy when handling complex molecular structure analysis, preclinical trial data simulation, and biological sequence work, shortening research timelines from experiments to clinical applications.

AI healthcare and biotech are a key focus for Anthropic

Anthropic has recently been actively publishing AI application tools for the healthcare industry, including Claude for Life Sciences released in late 2024 and Claude for Healthcare released in early 2025. Eric Kauderer-Abrams, the company’s head of biology and life sciences, said that healthcare and life sciences are the company’s biggest strategic direction at present. Anthropic’s goal is to ensure its models seamlessly integrate with the professional tools scientists use every day. This development path is similar to OpenAI’s ChatGPT Health—both companies are competing for entry into the AI biotech market.

Despite its aggressive technology push, Anthropic still faces regulatory and policy interference in the U.S. In March 2026, the U.S. Department of Health and Human Services (HHS) told employees to disable Claude tools, primarily because the government’s administrative branch was considering adding the company to a specific restrictions list. The ban also had a ripple effect on the U.S. Food and Drug Administration (FDA), affecting the progress of its earlier adoption of an AI tool called “Elsa” to accelerate drug review. Under the dual pressures of uncertainty in the regulatory environment and intensifying industry competition, Anthropic strengthens its life sciences expertise and technical capabilities by acquiring Coefficient Bio—reflecting that the company is trying to build a deep moat of specialized knowledge in order to secure its competitive position in a highly specialized market.

This article “Anthropic Acquires AI Biotech Startup Coefficient Bio for $400 Million” first appeared on Lian News ABMedia.